Covis Pharma S.à.r.l.
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Covis Pharma S.à.r.l. sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Covis Pharma S.à.r.l.: 3 sponsored US clinical trials, none currently recruiting.
Covis Pharma S.à.r.l. sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Raynaud's Phenomenon Secondary to Connective Tissue Disease, with 1 trials.
Upper-quartile sponsor footprint
Covis Pharma S.à.r.l. sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
NCT04377711
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
NCT02688270
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
NCT00458835
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
How the Covis Pharma S.à.r.l. archive is shaped
3 indexed studies, none listed as recruiting (0% open); 3 completed (100%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Raynaud's Phenomenon Secondary to Connective Tissue Disease (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Covis Pharma S.à.r.l.: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Covis Pharma S.à.r.l. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Covis Pharma S.à.r.l. page
3 registered trials is a research-attention snapshot, not an endorsement of Covis Pharma S.à.r.l. or any single study.
- None of Covis Pharma S.à.r.l.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Raynaud's Phenomenon Secondary to Connective Tissue Disease is the condition Covis Pharma S.à.r.l. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Raynaud's Phenomenon Secondary to Connective Tissue Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Covis Pharma S.à.r.l. pipeline card: 3 registered trials from official public datasets.Report a data error.